English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17524/19853 (88%)
Visitors : 6432736      Online Users : 736
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/28251


    標題: 活體造影內生性葡萄糖醛酸活性以進行個人化前驅藥物之標靶治療(II)
    In vivo imaging of endogenous ?-glucuronidase activity for personalized glucuronide prodrug targeted therapy
    作者: 呂玉玲
    鄭添祿
    貢獻者: 嘉南藥理大學藥學系
    日期: 2013
    上傳時間: 2014-11-05 15:30:14 (UTC+8)
    摘要: 直接測試不同腫瘤細胞內bG-activities, 不同腫瘤細胞間內生性bG-的活性並不相同, 異體移植不同細胞的腫瘤間內生性bG-的活性也不相同, 切片測試和活體照影的結果並不致.利用葡萄醣醛酸造影劑活體評估葡萄醣酸前驅藥物(9-ACG)和CPT-11之標靶治療的療效, 以NIR-TrapG評估bG活性, 與9ACGM的治療效果呈正相關, 另外, 造影劑有bG-活性表現的腫瘤colon 205, 當以CPT-11治療時, 對腫瘤生長的抑制作用比沒有bG-活性表現的腫瘤HCT116明顯有效.
    In vivo imaging to detect the endogenous b-glucuronidase activity, these have difference amounts of b-glucuronidase activity. Evaluate the therapeutic effect of glucuronide prodrug (9-ACG) in colon tumor, its effect equal with b-glucuronidase activity. Evaluate the therapeutic effect of glucuronide prodrug (CPT-11) in colon tumor with different b-glucuronidase activity, it is efficiency against tumor with highly b-glucuronidase activity than less level.
    關聯: 計畫編號:NSC101-2320-B041-001-MY2
    計畫年度:102;起迄日期:2013-08-01~2014-07-31
    Appears in Collections:[藥學系(所)] 科技部計畫

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML493View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback